Are CGRP Inhibitors Safe for Hemiplegic Migraine?

Yes, emerging evidence suggests that the newer classes of migraine medications—CGRP monoclonal antibodies (preventive shots or IV infusions) and gepants (acute or preventive pills/nasal sprays)—are generally considered safe and potentially highly effective off-label options for people with hemiplegic migraine ^[1][2]. For years, patients with hemiplegic migraine have been excluded from major clinical trials for new migraine drugs due to historical concerns about stroke risk. However, because these new treatments do not constrict blood vessels, headache specialists are increasingly prescribing them to hemiplegic migraine patients with promising results ^[3][4].

Why These Medications Are Different

For decades, the standard acute treatment for severe migraines has been triptans, a class of drugs that work partly by causing vasoconstriction (the narrowing of blood vessels). Because a hemiplegic migraine attack involves stroke-like symptoms and temporary motor weakness, doctors have long warned against using triptans, fearing that narrowing blood vessels could worsen an attack or increase the risk of a stroke.

The newer medications work differently. They target calcitonin gene-related peptide (CGRP), a protein in the brain and nervous system that causes inflammation and pain during a migraine attack.

• CGRP monoclonal antibodies (such as Aimovig, Ajovy, Emgality, and Vyepti) use immune system proteins to block CGRP or its receptor. These are typically used for prevention.
• Gepants are small molecules that block the CGRP receptor. Some are used to stop an active attack (such as Ubrelvy and Zavzpret), while others are used to prevent them (like Qulipta) or both (like Nurtec ODT).

Crucially, neither of these drug classes causes measurable constriction of cerebral (brain) or meningeal arteries ^[4][5]. Because they do not rely on vasoconstriction to stop a migraine, they do not appear to worsen cerebral ischemia (a lack of blood flow to the brain) ^[3]. This makes them a valuable and much safer alternative for patients who have cardiovascular or cerebrovascular risk factors and cannot take triptans ^[6][7].

What the Emerging Research Shows for Hemiplegic Migraine

Because hemiplegic migraine is a rare subtype of migraine, large-scale studies are still catching up ^[1]. The strongest data we currently have focuses on the preventive use of CGRP monoclonal antibodies. Early data from case reports, small observational studies, and systematic reviews is very encouraging ^[1][8].

In a recent systematic review of patients with hemiplegic migraine who were treated preventively with anti-CGRP monoclonal antibodies, the findings showed:

• Significant Reduction in Aura: Patients saw a statistically significant drop in their monthly days with aura (which includes motor weakness and paralysis), dropping from a median of 3 days to less than 1 day per month ^[1].
• Less Disability: Patients experienced a substantial decrease in their Migraine Disability Assessment (MIDAS) scores ^[1].
• High Success Rates: 83% of the patients achieved a greater than 50% reduction in both their monthly headache days and their aura frequency ^[1].
• Safety Profile: These therapies were well-tolerated with no severe adverse events or worsening of neurological symptoms reported in the reviewed studies ^[1][8]. However, patients should be aware that while they lack cardiovascular risks, they can still cause common, non-neurological side effects like injection site reactions, constipation, nausea, or fatigue.

Note on Acute Treatment: While gepants are considered safe because they do not constrict blood vessels, research specifically measuring their success rate in stopping an active hemiplegic migraine attack (acute treatment) is still limited. Headache specialists are increasingly using them in practice, but clinical trial data has yet to definitively measure their acute efficacy for the hemiplegic subtype.

Important Considerations for Patients

While the safety profile is highly favorable, there are a few things to keep in mind as you discuss these options with your medical team:

• Off-Label Use: Because hemiplegic migraine patients were excluded from the initial trials for FDA approval, prescribing these medications for this specific condition is considered “off-label” ^[1]. This is a standard and legal practice, but it may require your doctor to provide extra documentation for insurance coverage.
• Heart and Vascular Health: Even though gepants and CGRP inhibitors lack cardiovascular contraindications, doctors may still exercise clinical caution if you have a history of cardiovascular or cerebrovascular disease (like a previous stroke), as long-term safety data in these specific high-risk groups is still being gathered ^[9][10].
• Need for Specialized Care: Due to the complexity of familial and sporadic hemiplegic migraine, treatment should be managed by a neurologist or a dedicated headache specialist who stays current with emerging research ^[1].